Backed by strong investor demand, Supriya Lifescience Ipo subscribed 71.52 times on a closing day.
Having a good financial track record is the key to success in an Ipo market. Supriya life science proved it on the closing day of subscription for its IPO.
The initial public offering by Supriya Lifesciences ended today with strong- demand from investors. The pharmaceutical ingredients manufacturer and supplier received bids for 103.89 crore shares against an offer of 1.45 crore equity shares.
Retail investors showed interest by subscribing 55.99 times; non-institutional investors subscribing 161.22 times; qualified institutional investors subscribing 31.83 times. The offer for sale at rs. 265–275 per share opened on 16th December 2021 for subscription and ended on 20th December 2021.
Prices on the upper hand of the offer at 275 seem justified and reasonable compared with some of the peer companies. Brokerage firms insisted on subscribing to the Ipo of Supriya life sciences, and good overall ratings of 4.5 on brokerage review sites made the offer lucrative for investors.
Even before the opening of the initial public offering, Supriya Lifesciences shares gained a premium on the grey market. As of March 2021- Supriya Lifesciences manufacture 38 APIs focussing on diverse therapeutic segments like anti-allergic, analgesic, antihistamine, anesthetic, vitamin, and anti-asthmatic.
Supriya Lifesciences- export materials like Chlorpheniramine Maleate and Ketamine Hydrochloride since 2017 in large numbers. In 2021 the company exported Salbutamol Sulphate in large numbers from India.
Supriya Lifescience primarily exports products to 86 countries including, Europe, Latin America, North America, and Asia. It does business with 1296 customers across the globe with having a network of 346 distributors worldwide.
With manufacturing facilities spread across 23,806 sp. mt in Maharashtra and acquiring 12,551 sq. mt land near the same plant for expansion added the manufacturing capacities for the company.
Supriya Lifescience plans to utilize the funds from the initial public offering towards a general-purpose fund, repayment of the debt, pre-payment, or part of certain borrowings.
Supriya Lifescience received a subscription: QIB(Qualified Institutional Investors)-31.83 times, NII(Non-Institutional Bidders)-161.22 times, and Retail Investors-56.01 times.
Standalone profit for the period ended 31st March 2021 stands to 1238.28 compared with 733.74 in 2020 and 394.24 in 2019.
Standalone profit for the period- ended on 31st March 2021, stands at 1238.28 compared with 733.74 in 2020 and 394.24 in 2019.
The expected date for the allotment of shares is December-23rd, the refund date is 24th, and the date- of- listing is December-28th.
The current grey market premium and listing gains to be around 180–200 premium on the offer price. The data derived from market speculators and actual profit may vary.
On a listing day, expect gains in good numbers as the company offers good long-term prospects.
Disclaimer; Views expressed here are personal, and actual gains vary depending on the market condition on a particular day.
